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Abstract
Based on the life-time cost to the health care system, the Institute of Medicine has assigned the highest priority for a vaccine to
control human cytomegalovirus (HCMV) disease in transplant patients and new born babies. In spite of numerous attempts
successful licensure of a HCMV vaccine formulation remains elusive. Here we have developed a novel chimeric vaccine strategy
based on a replication-deficient adenovirus which encodes the extracellular domain of gB protein and multiple HLA class I & II-
restricted CTL epitopes from HCMV as a contiguous polypeptide. Immunisation with this chimeric vaccine consistently
generated strong HCMV-specific CD8
+ and CD4
+ T-cells which co-expressed IFN-c and TNF-a, while the humoral response
induced by this vaccine showed strong virus neutralizing capacity. More importantly, immunization with adenoviral chimeric
vaccine also afforded protection against challenge with recombinant vaccinia virus encoding HCMV antigens and this
protection was associated with the induction of a pluripotent antigen-specific cellular and antibody response. Furthermore, in
vitro stimulationwiththis adenoviral chimeric vaccine rapidly expanded multiple antigen-specific humanCD8
+ and CD4
+ T-cells
from healthy virus carriers. These studies demonstrate that the adenovirus chimeric HCMV vaccine provides an excellent
platform for reconstituting protective immunity to prevent HCMV diseases in different clinical settings.
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Introduction
Human cytomegalovirus (HCMV) is a classic example of a group
of herpes viruses, which is found universally throughout all
geographic locations and socioeconomic groups, and infects 50%
of adults in developed countries [1]. Although HCMV does not
cause clinical disease in immunocompetent individuals except as a
mononucleosis-like illness which is observed in a small number of
infected individuals, HCMV infection is important to the following
three high-risk groups: 1) unborn babies with an immature immune
system, 2) people who work with children, and 3) immunocom-
promised people such as organ transplant patients and HIV-
infected individuals) [1]. Epidemiological studies have shown that
15%–30% of unborn babies who acquire congenital HCMV
infection display a variable pattern of pathological sequelae within
the first few years of life that may include hearing loss, vision
impairment and mental retardation [2]. It has been estimated that
in the US alone, each year 8000 newborns have health problems as
a results of congenital HCMV infection, with each child costing the
US health care system more than $300,000 [3]. Based on the cost
and human suffering that would be relieved by reducing the disease
burden associated with HCMV infection, the development of a
vaccine to prevent HCMV infection or disease was assigned the
highest priority, together with vaccines for HIV, TB and Malaria,
by the Institute of Medicine (USA) in 1999 [4].
It is now well documented that both humoral and cellular
(including CD4
+ Tc e l l sa n dC D 8
+ Tc e l l s )i m m u n er e s p o n s e sp l a y
an important role in the control of HCMV infection and disease
[1,5]. Therefore a formulation based on viral antigens that activate
both humoral and cellular immunity is crucial for a successful
HCMV vaccine [6,7]. During the last 30 years, various strategies,
including whole virus, subunit vaccines based on recombinant gB
protein, vector vaccines expressing immunodominant antigens (gB
protein, pp65 and/or IE-1 protein), DNA vaccine and dense bodies
have been developed, and some of these formulations have shown
encouraging results in preclinical studies and can even induce
HCMV-specific immune responses in some clinical studies
[8,9,10,11].However,noneofthesevaccineshave shownconvincing
clinical efficacy in the control of HCMV infection or disease, and a
clinically licensed HCMV vaccine is still not available.
In recent years, increasing evidence has shown that HCMV-
specific immune responses are not restricted to gB, pp65 and IE-1
antigens as previously understood, but are directed towards more
than 70% of the HCMV reading frames [12,13,14,15]. Therefore,
a vaccine which can induce a broad repertoire of HCMV-specific
immune responses in different ethnic populations is likely to
provide more effective protection against virus-associated patho-
genesis. To achieve this goal, we have designed a novel chimeric
vaccine based on a replication deficient adenovirus which encodes
46 HCMV T cell epitopes from 8 different HCMV antigens,
restricted through multiple HLA class I and Class II alleles, as a
polyepitope [16]. This polyepitope was covalently linked to a
truncated form of HCMV-encoded gB antigen which allowed the
expression of the HCMV polyepitope and gB proteins as a single
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epitope vaccine in HLA A2 transgenic mice (referred to as HHD-
2) and humans showed that this formulation is capable of inducing
pluripotent cellular and humoral immunity in vivo and also readily
recalls and expands HCMV-specific CD8
+ and CD4
+ T cells.
Results
Immunisation of HHD-2 mice with Ad-CMVpoly and/or
Ad-gB vaccine induces multiple antigen-specific cellular
and humoral immunity
Recent studies on the immune regulation of HCMV in healthy
virus carriers and transplant patients have clearly indicated that
long-term protection from viral pathogenesis is critically depen-
dent on the induction of cellular immunity which is directed
towards multiple viral antigens expressed during different stages of
HCMV infection [12,13,14,15,17]. In the first set of experiments
we specifically designed our vaccine strategy to induce a cellular
immune response against multiple antigens of HCMV using the
polyepitope technology [18]. HLA A2 transgenic mice (referred to
as HHD-2) were immunised (intramuscularly) with an adenoviral
vector encoding 46 HLA class I and II-restricted T cell epitopes as
a polyepitope (referred to as Ad-CMVpoly; 7.5610
8 pfu/mouse;
Figure 1 and Table 1). Ten days after immunisation, ex vivo T cell
reactivity to the HLA A2-restricted peptide epitopes (pooled; see
Table 1) was assessed by ELISPOT technology. It is important to
mention here that the virus dosage for vaccination was selected
based on our preliminary studies where a range of varying doses
were investigated (data not shown). Splenocytes were used as
responder cells for the detection of epitope-specific T cells. Data
presented in Figure 2A shows that we consistently observed a
strong HCMV epitope-specific T cell response following Ad-
CMVpoly vaccination. Analysis of T cell responses to the
individual epitopes within the polyepitope sequence indicated that
during primary immunisation the dominant T cell response was
directed towards the VLE epitope derived from IE-1 antigen,
although subdominant responses towards other HLA A2-restricted
epitopes NLV (pp65), RIF (pp65), VLA (IE-1), IIY (IE-2) AVG
(gB) was also detected (Figure 2B).
Recent studies have raised some concerns on the use of
adenoviral vectors in humans as the pre-existing immunity to
adenovirus may compromise the efficacy of these vaccine
formulations [19,20,21]. To explore this issue, Ad-CMVpoly
immunized HHD-2 mice were rested for one or three months and
Figure 1. Schematic representation of the construction of a recombinant adenovirus that expresses a synthetic DNA encoding for a
polyepitope protein which contains 46 HCMV T-cell epitopes (see box and Table 1). Each of the alternate epitope sequences are shown in
bold letters. The DNA sequence encoding this polyepitope protein was constructed using overlapping epitope sequence specific primers (referred to
as CMV1 to CMV20) as described in the ‘‘Material and Methods’’ section. This synthetic insert was first cloned into a pBluescript II KS
+ phagemid, prior
to cloning into the pShuttle vector. After amplification in E.coli, the expression cassette from pShuttle was excised and ligated into the Ad5F35
expression vector. Following linearization of the DNA using Pac I restriction enzyme, the recombinant Ad5F35 vector was packaged into infectious
adenovirus by transfecting HEK 293 cells, and recombinant adenovirus (referred to as Ad-CMVpoly) was harvested from transfected cells by repeated
freeze-thawing cycles.
doi:10.1371/journal.pone.0003256.g001
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Epitope order
number
Epitope
Sequences
HLA
restriction
HCMV
Antigens
Parent
protein (UL)
Amino acid
location
Abbreviated
code Reference
1 VTEHDTLLY A1 pp50 UL44 245–253 VTE [13]
2 KPGKISHIMLDVA B35/DR3 pp65 UL83 283–295 KPG [13]
3 NTDFRVLEL A1 gB UL55 657–665 NTD [13]
4 VLEETSVML A2 IE1 UL123 316–324 VLE [13]
5 NLVPMVATV A2 pp65 UL83 495–503 NLV [55]
6 RIFAELEGV A2 pp65 UL83 522–530 RIF [13]
7 IIYTRNHEV A2 IE2 UL122 244–251 IIY [16]
8 CVETMCNEY A1 IE1 UL123 279–287 CVE [13]
9 VLAELVKQI A2 IE1 UL123 81–89 VLA [13]
10 AVGGAVASV A2 gB UL55 731–739 AVG [13]
11 TVRSHCVSK A3 pp50 UL44 52–60 TVR [13]
12 IMREFNSYK A3 gB UL55 682–690 IMR [13]
13 GPISHGHVLK A11 pp65 UL83 16–24 GPI [56,57]
14 AYAQKIFKIL A23/A24 pp65? UL83 248–257 AYA [13]
15 QYDPVAALF A24 pp65 UL83 341–349 QYD [13]
16 YVKVYLESF A26 pp65 UL83 223–231 YVK [13]
17 DIYRIFAEL A26 pp65 UL83 519–527 DIY [13]
18 VFETSGGLVV A29 gB UL55 420–429 VFE [56,57]
19 KARDHLAVL B7 pp150 UL32 101–109 KARD [13]
20 KARAKKDEL B7/B8 IE1 UL123 192–200 KARA [13]
21 TRATKMQVI B57/B58/Cw6 pp65 UL83 211–219 TRA [13]
22 HELLVLVKKAQL DR11 gH UL75 276–287 HEL [58]
23 DDYSNTHSTRYV DR7 gB UL55 216–227 DDY [58]
24 QIKVRVDMV B8 IE1 UL123 88–96 QIK [13]
25 RRRHRQDAL B8/B27 pp65 UL83 539–547 RRR [13]
26 ARVYEIKCR B27 DNAse UL98 274–282 ARV [13]
27 NVRRSWEEL B7 pp150 UL32 212–220 NVR [13]
28 CPSQEPMSIYVY B35 pp65 UL83 103–114 CPS [16]
29 QARLTVSGL B7 pp65 UL83 158–166 QAR [13]
30 ELKRKMMYM B8 IE1 UL123 199–207 ELK [13]
31 IPSINVHHY B35 pp65 UL83 123–131 IPS [59]
32 FEQPTETPP B41 IE2 UL122 381–389 FEQ [16]
33 YAYIYTTYL B41 gB UL55 153–161 YAY [16]
34 QEFFWDANDIY B44/DRw52 pp65 UL83 511–521 QEF [13]
35 YEQHKITSY B44 pp50 UL44 372–380 YEQ [13]
36 QEPMSIYVY B44 pp65 UL83 106–114 QEP [13]
37 SEHPTFTSQY B44 pp65 UL83 364–373 SEH [13]
38 QAIRETVEL B57/B58 pp65 UL83 331–339 QAI [16]
39 CEDVPSGKL B40/60 pp65 UL83 232–240 CED [60]
40 KMQVIGDQY B40/60 pp65 UL83 215–223 KMQ [60]
41 ATVQGQNLK A11 pp65 UL83 501–509 ATV [60]
42 HERNGFTVL B40/60 pp65 UL83 267–275 HER [60]
43 DALPGPCI B51 pp65 UL83 546–552 DAL [60]
44 VYALPLKML A24 pp65 UL83 113–121 VYA [61]
45 PTFTSQYRIQGKL B38/DR11 pp65 UL83 367–379 PTF [55,62]
46 QMWQARLTV B52 pp65 UL83 155–163 QMW [30]
doi:10.1371/journal.pone.0003256.t001
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8 pfu/
mouse). Although secondary immunization of mice after one
month of vaccination showed very minimal increase in the T cell
response (data not shown), a 3–5 fold increase in the T cell
response was observed in HHD-2 mice vaccinated after three
months of their primary vaccination (Figure 2C). More impor-
tantly, following secondary immunization, a small but significant
increase in the subdominant responses was observed in some
animals, while the T cell response towards VLE epitope remained
the most dominant component of overall response (Figure 2D). It
Figure 2. HCMV epitope-specific T cell response following primary and secondary immunisation with Ad-CMVpoly vaccine. Two
different groups of HHD-2 mice were immunised intramuscularly with Ad-CMVpoly (7.5610
8 PFU/mouse). A&B , Following primary immunisation,
animals were sacrificed 10 days post immunisation and HCMV epitope-specific reactivity was assessed in the splenocytes by ELISPOT assays as
described in the ‘‘Material and Methods’’ section. The epitopes tested for T cell reactivity were VLE (IE-1), NLV (pp65), RIF (pp65), VLA (IE-1), IIY (IE-2)
AVG (gB). C&D , For immunological analysis following secondary immunisation, animals were given booster immunisation (7.5610
8 PFU/mouse) 100
days after primary immunisation and then sacrificed 10 days post secondary immunisation. HCMV epitope-specific reactivity was assessed as
described above. A&Cshows ELISPOT data based on the pooled HLA A2-restricted HCMV epitopes, while B&Dshows relative T cell responses to
individual epitopes. The results are expressed as Mean6SE of spot forming cells (SFC) per 10
6 splenocytes from four individually tested mice. E, Anti-
adenovirus antibody titre induced by immunisation with Ad-CMVpoly. Serum samples were collected at different time points after immunisation and
anti-adenovirus titres were evaluated by ELISA as described in the ‘‘Material and Methods’’ section. All statistical analyses were conducted using
GraphPad Prism 4 software.
doi:10.1371/journal.pone.0003256.g002
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in HHD-2 mice was very similar to that observed in HLA A2-
positive healthy virus carriers [12,13,14]. This observation was co-
incident with the dramatic decline of antibodies against adenovirus
vector 2 to 3 months after immunisation with Ad-CMVpoly
(Figure 2E).
Combination of Ad-CMVpoly and Ad-gB induces long
lasting memory cellular and humoral immune responses
It is now firmly established that although T cell responses play an
important role in controlling persistent HCMV infection, humoral
immune responses also contribute significantly in controlling
primary HCMV infection and as well reduce viral load by
neutralizing the extra-cellular virus [22,23]. To ensure that our
vaccine strategy can induce both cellular and humoral immune
responses, we immunised HHD-2 mice with the mixture of Ad-gB
(7.5610
8 pfu/mouse) and Ad-CMVpoly (7.5610
8 pfu/mouse), and
anti-HCMV specific cellular and humoral immune responses in
immunised animals were evaluated at different time point by
ELISPOTandELISArespectively.DatapresentedinFigure3A&B
shows that this vaccination strategy induced both CD8
+ Tc e l l sa n d
gB-specific antibody responses. The levels of CD8
+ T cells induced
bythis co-immunisation strategywerecomparabletothose seenwith
Ad-CMVpolyaloneand weredetectableat reasonablyhighlevelson
day 75 post-immunisation (Figure 3A). The levels of gB-specific
antibody responses were maintained at high levels by day 75 post-
immunisation, although a small reduction was observed when
compared to the levels observed on days 10 and 25 respectively. In
contrast, the antibody response showed significant increase in the
virus neutralization capacity by day 75 post-immunisation
(Figure 3C) which was co-incident with the antibody avidity
maturation (Figure 3D). It is important to mention here that this
increase in neutralization capacity was not due to antibody isotype
switching (Figure 3E), which was consist with previous studies [24].
These observations suggested that co-delivery of HCMV polyepi-
tope and gB vaccine can induce long lasting memory T cells
immunity and antibody responses.
Covalent linking of HCMV polyepitope with extracellular
gB induces pluripotent T cell and antibody responses
Although co-immunisation with Ad-gB and Ad-CMVpoly
induced both humoral and cellular immune responses against
HCMV, delivery of this formulation in a human setting may face
significant regulatory constraints. To overcome this potential
limitation, we constructed another recombinant adenovirus express-
ing the extracellular domain of gB and HCMV polyepitope as a
single polypeptide (referred as Ad-gBCMVpoly). HHD-2 mice were
immunised with the Ad-gBCMVpoly vaccine (7.5610
8 pfu/mouse)
and both humoral and cellular immune responses were evaluated at
the indicated time points. Data presented in Figure 4A shows that
immunisation with Ad-gBCMVpoly vaccine induced a long-tem
memory CD8
+ T cell response towards the HLA A2-restricted
epitopes from HCMV. Furthermore these animals also showed
strong gB-specific antibody response and similar to the data
presented in Figure 3B, the levels of gB-specific antibody dropped
by day 75 post immunisation (Figure 4B). A significant increase in
the neutralizing activity of the antibody response was observed
(Figure 4C), which was co-incident with avidity maturation
(Figure 4D). On the other hand, there was no antibody isotype
switching at different time point after immunisation (Figure 4E).
These observations clearly demonstrated that covalent linking of the
gB with the polyepitope sequence does not impair the immunoge-
nicity of each of the components of the vaccine.
To further characterize the T cell responses induced by Ad-
gBCMVpoly vaccine, we next assessed whether immunisation with
Ad-gBCMVpoly result in the differentiation of antigen-specific T
cells into fully functional effectors. A number of recent studies have
demonstrated that the production of TNF-a in addition to IFN-c
by T-cells is a characteristic of greater differentiation and can
enhance protection against infectious pathogens [25,26], and the
translocation of CD107a from intracellular lysosomal and
endosomal compartments to the surface of CD8
+ T cells is a
positive marker of degranulation, a requisite process of perforin-
granzyme mediated killing function of CTLs [27,28]. We assessed
the level of TNF-a and/or CD107a expression by IFN-c
expressing CD8
+ T-cells using intracellular cytokine assays. Data
presented in Figure 5A–B shows that following ex vivo stimulation
with HCMV epitopes, CD8
+ T cells from these mice showed
strong IFN-c expression and a large proportion of these T cells
also expressed TNF-a and/or CD107a. Furthermore, after in vitro
stimulation with individual HCMV peptides, these HCMV
peptide-specific CD8
+ T cells could be expanded and expressed
both IFN-c and TNF-a (Figure 5C–E).
Protection against quasi-virus challenge following
immunisation with Ad-gBCMVpoly
Having firmly established the immunogenicity of Ad-
gBCMVpoly vaccine, the next set of experiments was designed
to determine protective efficacy of this vaccine. Due to the species
restriction, we challenge immunised HHD-2 mice with recombi-
nant vaccinia encoding HCMV antigens (gB and IE-1) to evaluate
the protective efficiency of the Ad-gBCMVpoly vaccine. Data
presented in Figure 6A shows that HLA A2 mice immunised with
Ad-gBCMVpoly vaccine showed significant reduction in the virus
load following challenge with Vacc.gB and Vacc.IE-1. This
reduction in the virus load was highly antigen-specific as the
vaccinated or naı ¨ve animals challenged with Vacc.TK- or
Vacc.gB, Vacc.IE-1 respectively showed minimal reduction in
the viral load. Although Ad-gBCMVpoly immunized mice showed
better protection against Vacc.gB when compared to Vacc.IE-1
(Figure 6A), this better protection was not due to anti-gB
antibodies (Figure 6B) as Vacc.gB was not neutralized by serum
from immunized animals (data not shown), but due to gB-specific
CD4
+ T cell responses (Figure 6C). Nevertheless, the anti-gB
humoral response should play an important role in human as it
induces HCMV neutralizing antibodies. As expected, the
reduction in the Vacc.IE-1 virus load in Ad-gBCMVpoly
immunised mice was co-incident with the induction of VLE-
specific CD8
+ T cell responses (Figure 6D). It is important to note
that Ad-gBCMVpoly immunised mice challenged with Vacc.gB or
Vacc.IE-1 showed significantly higher humoral and T cell
responses respectively when compared to mice challenged with
Vacc.TK-. We also assessed the level of TNF-a expression by IFN-
c expressing CD4
+ and CD8
+ T-cells using intracellular cytokine
assays. Data presented in Figure 6E shows that following
stimulation with gB protein or HCMV IE-1 epitope, a large
proportion of CD4
+ and CD8
+ T cells from these mice showed
strong co-expression of IFN-c and TNF-a.
Expansion of multiple antigen-specific human CD8
+ and
CD4
+ T cells following stimulation with Ad-gBCMVpoly
Another important aspect of the current study was aimed at
exploring the potential efficacy of Ad-gBCMVpoly to recall
memory T cell responses from healthy seropositive individuals.
PBMC from healthy donors were stimulated with irradiated
autologous PBMC-infected with Ad-gBCMVpoly. Following
Prophylactic Vaccine for HCMV
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intracellular cytokine assays. Data for the gB-specific CD4
+ and
CD8
+ T cell responses are summarised in Figure 7, while the T cell
responses towards the epitopes within the polyepitope sequence are
presented in Tables 2 & 3. To identify the gB-specific T cell
responses we used an overlapping set of peptides based on the gB
sequence from Ad169 strain of HCMV. This analysis showed that
following stimulation with Ad-gBCMVpoly, more than 88% of the
individuals showed expansion of gB-specific CD4
+ T cells. These T
cell expansions raged from 2–36% of the total CD3
+ CD4
+ Tc e l l s
Figure 3. HCMV-specific effector and memory cellular and humoral immune responses following immunisation with a mixture of
Ad-CMVpoly and Ad-gB vaccines. A, HCMV-specific CD8+ T cell responses following immunisation with Ad-CMVpoly and Ad-gB. These T cell
responses were assessed using ELISPOT assays on day 10, 25 and 75 post immunisation. The results are expressed as Mean6SE of spot forming cells
(SFC) per 10
6 splenocytes. B, gB-specific antibody responses in serum samples from immunised mice on days 10, 25 and 75. Serum samples on day 0
were collected before the immunisation. C, Virus neutralizing capacity of antibody responses induced in HHD-2 mice immunised with Ad-CMVpoly
and Ad-gB. Serum samples from these mice were pre-incubated with HCMV virus Ad169 and then these virus preps were used to infect MRC-5.
Following overnight incubation virus infectivity was assessed using IE-1/IE-2 expression as outlined in the ‘‘Material and Methods’’ section. D, Avidity
maturation of gB-specific antibody responses in Ad-CMVpoly and Ad-gB immunised mice. E, Immunoglobulin subclass analysis of gB-specific
antibody responses in HHD-2 vaccinated mice. Serum samples were collected from three different groups of mice on days 10, 25 and 75 post-
immunisation. A minimum of five mice from each group were assessed for HCMV epitope-specific T cell reactivity and humoral immune responses. All
statistical analyses were conducted using GraphPad Prism 4 software.
doi:10.1371/journal.pone.0003256.g003
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+ T cell responses directed towards gB epitopes were
detected in 70.5% donors which ranged from 2–15% of the total
CD3
+ CD8
+ T cells. T cells from each donor recognized multiple gB
epitopes and most of the donors demonstrated a selective expansion
of gB-specific CD4
+ or CD8
+ Tc e l l s .
Analysis of the T cell responses towards the epitopes within the
polyepitope sequence revealed that there was a rapid expansion of
CD8
+ T cells following stimulation with Ad-gBCMVpoly which
recognized multiple epitopes restricted through a number of HLA
class I alleles (Table 2). In most cases, dominant CD8
+ T cell
expansions directed towards 2–3 different epitopes was observed;
whilst in other donors (e.g. D9, D10 and D13) strong T cell
reactivity towards more than five epitopes was observed. In vitro
testing of these T cells also showed that these cells expressed high
Figure 4. HCMV-specific effector and memory humoral and cellular immune responses following immunisation with Ad-
gBCMVpoly vaccine. A, HCMV-specific CD8+ T cell responses following immunisation with Ad-gBCMVpoly. These T cell responses were assessed
using ELISPOT assays on day 10, 25 and 75 post immunisation. The results are expressed as Mean6SE of spot forming cells (SFC) per 10
6 splenocytes.
B, gB-specific antibody responses in serum samples from immunised mice on days 10, 25 and 75. Serum samples on day 0 were collected before the
immunisation. C, Virus neutralizing capacity of antibody responses induced following immunisation with Ad-gBCMVpoly. Serum samples from these
mice were pre-incubated with HCMV virus Ad169 and then these virus preps were used to infect MRC-5. Following overnight incubation virus
infectivity was assessed using IE-1/IE-2 expression as outlined in the ‘‘Material and Methods’’ section. D, Avidity maturation of gB-specific antibody
responses in Ad-gBCMVpoly immunised mice. E, Immunoglobulin subclass analysis of gB-specific antibody responses in HHD-2 vaccinated mice.
Serum samples were collected from three different groups of mice on days 10, 25 and 75 post-immunisation. A minimum of five mice from each
group were assessed for HCMV epitope-specific T cell reactivity and humoral immune responses. All statistical analyses were conducted using
GraphPad Prism 4 software.
doi:10.1371/journal.pone.0003256.g004
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infected target cells (data not shown). These observations were also
confirmed by ex vivo stimulating the PBMC from healthy virus
carriers with Ad-gBCMVpoly. A representative data presented in
Figure 8 clearly shows that ex vivo stimulation of PBMC rapidly
stimulated HCMV epitope specific T cells and these cells showed
strong expression of IFN-c. Although the polyepitope sequence
was predominantly based on CD8
+ T cell epitopes, two previously
mapped CD4
+ T cell epitopes were also included in this sequence.
As expected, a strong expansion of CD4
+ T cells specific for these
epitopes was observed, however unexpectedly, we also detected
low to medium levels of expansion of CD4
+ T cells which showed
reactivity against HLA class I-restricted CD8
+ T cell epitopes
(Table 3). A careful analysis of these CD8
+ T cell epitopes revealed
that many of these sequences overlapped the CD4 epitopes
mapped recently by other investigators [29,30,31].
Discussion
The data presented in this study provides a highly efficient
strategy for the prevention of HCMV disease in different clinical
settings ranging from congenital infection to primary or reactiva-
tion of the virus in immunosuppressed adults. The importance of
HCMV as the leading infectious cause of mental retardation and
other abnormalities such as deafness in children has been
emphasized by its categorization by the Institute of Medicine as
a Level I vaccine candidate [i.e. most favourable impact–saves
both money and quality-adjusted life years] [4]. Immunocompro-
mised individuals such as transplant recipients and HIV-infected
individuals with CD4 counts below 50/ml are also impacted by
HCMV infection and this virus is regarded as the most important
viral pathogen affecting transplantation, including both solid
organ transplant and allogeneic hematopoietic stem cell transplant
Figure 5. Cytokine expression by HCMV-specific CD8
+ T cells from Ad-gBCMVpoly immunised HHD-2 mice. A&B ,Ex vivo expression of
IFN-c, TNF-a and CD107a by antigen-specific CD8
+ T-cells from Ad-gBCMVPpoly vaccinated mice 10 days post-vaccination. Splenocytes were
prepared from 3 individual HHD-2 mice 10 days post-vaccination and cultured with individual HCMV peptides overnight. Anti-CD107a antibody and
Brefeldin A was added during the last 6 and 5 hours incubation respectively, followed by T cell surface marker and intracellular cytokine staining.
Data represent the percentage of IFN-c expressing CD8
+ T cells (A) and percentage of single, double or triple markers expressing cells among IFN-c
expressing CD8
+ T cells (B). C–E, Expression of IFN-c and/or TNF-a by in vitro expanded antigen-specific CD8
+ T-cells from Ad-gBCMVPpoly vaccinated
mice 10 days post-vaccination. Splenocytes pooled from three immunised mice were first stimulated with individual HCMV peptide epitope-pulsed
splenocytes for 2 weeks in the presence of recombinant mouse IL-2 at the concentration of 10 IU/ml, then cultured with MRC-5 cells pulsed with
corresponding HCMV peptide epitope overnight for intracellular cytokine assay. The HCMV peptide epitopes tested here were VLE (IE-1), NLV (pp65),
RIF (pp65), VLA (IE-1) at the concentration of 1 mg/ml. Data represent the percentage of IFN-c (C), TNF-a (D) and IFN-c & TNF-a (E) expressing CD8
+ T-
cells. ** (p,0.005) and * (p,0.05) show statistically significant difference between indicated CMV peptide epitopes and control epitope (A). Data
from one out three experiments with similar results was shown in C–E. All statistical analyses were conducted using GraphPad Prism 4 software.
doi:10.1371/journal.pone.0003256.g005
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immunobiology of HCMV infection has provided detailed insight
into the immune regulation of persistent HCMV infection in
healthy virus carriers and individuals with HCMV-associated
diseases [1]. Based on these observations, a number of attempts
have been made to design a prophylactic vaccine for the control of
Figure 6. Ad-gBCMVpoly induced protection against challenge with recombinant vaccinia expressing gB or IE-1 protein. HHD-2 mice
were immunised with Ad-gbCMVpoly vaccine and 21 days following vaccination these mice were challenged (intraperitoneal) with recombinant
vaccinia encoding gB (Vacc.gB), IE1 protein (Vacc.IE-1) or control vaccinia (Vacc.TK
2)a t1 0
7 pfu virus/mouse. Ovaries, splenocytes and peripheral
blood samples were collected four days later and used for assessing viral load, antigen-specific T cell response and gB-specific antibody response. A,
Virus titres in the ovaries of Ad-gBCMVpoly immunised or naı ¨ve HHD-2 mice challenged with Vacc.IE-1, Vacc.gB or Vacc.TK
2. B, gB-specific antibody
response in Ad-gBCMVpoly immunised or naı ¨ve HHD-2 mice challenged with Vacc.gB or Vacc.TK
2. C, Ex vivo gB-specific CD3
+CD4
+ T cell response in
Ad-gBCMVpoly immunised or naı ¨ve HHD-2 mice challenged with Vacc.gB or Vacc.TK
2. Splenocytes from these mice were stimulated with
recombinant gB protein (40 mg/ml) overnight and then assessed for IFN-c production using intracellular cytokine assay. D, Ex vivo IE-1-specific
CD3
+CD8
+ T cell response in Ad-gBCMVpoly immunised or naı ¨ve HHD-2 mice challenged with Vacc.IE-1 or Vacc.TK
2. Splenocytes from these mice
were stimulated with the peptide epitope VLEETSVML (1 mg/ml) overnight and then assessed for IFN-c production using intracellular cytokine assay.
E, Ex vivo expression of IFN-c and/or TNF-a by antigen-specific CD8
+ and CD4
+T-cells from Ad-gBCMVPpoly vaccinated mice, challenged with
recombinant vaccinia encoding IE-1 or gB. Splenocytes from immunised mice stimulated with either gB protein or IE-1 peptide epitope overnight for
intracellular cytokine assay. Data represent the percentage of TNF-a and IFN-c & TNF-a expressing CD4
+ or CD8
+ T-cells. All statistical analyses were
conducted using GraphPad Prism 4 software.
doi:10.1371/journal.pone.0003256.g006
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of an attenuated form of the virus as a vaccine [6,8,34,35]
however, disappointing results coupled with the regulatory
problems associated with the live attenuated HCMV vaccine
prompted investigators to switch to the recombinant subunit
approach [36,37,38,39]. Although the subunit vaccine delivery
systems and modalities based on HCMV encoded antigens such as
gB, pp65 and IE-1 have failed to result in a licensed clinical
product, interesting pre-clinical (based on animal models) and
clinical data continues to accumulate demonstrating that subunit
vaccination has a protective effect against congenital transmission
[9,10,40,41,42].
It is now firmly established that long-term latent HCMV
infection is very efficiently controlled by virus-specific CD4
+ and
CD8
+ T cells [12,13,14,15,43]. Perturbation in the regulation of T
cell control often triggers reactivation of HCMV and development
of HCMV-associated diseases [17,44,45]. The concept that a
vaccine based on T cell-mediated control would be effective in
controlling HCMV diseases grew out of the pioneering work
conducted by Riddell and colleagues, who showed that adoptive
transfer of donor-derived virus-specific T cells alone were sufficient
to reduce the incidence of HCMV disease in allogeneic
hematopoietic stem cell transplant recipients [46,47]. Over the
last few years there has been a series of attempts to develop a
highly tailored vaccine strategy designed to induce T cell
immunity against pp65 and/or IE-1 antigens or defined T cell
epitopes from these antigens [38,48,49].
While these strategies provided specificity and safety, their
application at the population level are rather limited. Thus other
approaches which target multipleantigens might beanadvantage by
providing wider coverage in different ethnic groups. Furthermore,
inclusion of a virus neutralization component in the vaccine
formulation has been argued by many investigators, especially in
the context of congenital HCMV infection. Indeed the chimeric
vaccine developed in this study induced high avidity humoral
responses and cellular immunity with a single formulation and
provided wider coverage through the inclusion of multiple T cell
epitopes restricted through a range of HLA class I and II alleles. Our
initial studies with a mixture of adenoviral vectors encoding HCMV
polyepitope sequence and gB protein showed that it was possible to
induce both humoral and cellular immune responses without
compromising the immunogenicity of individual components of
the vaccine. Taking into consideration these observations, we
designed a chimeric vaccine in which the encoding sequence for
the extracellular domain of gB was covalently linked with the
polyepitope sequence. Extensive studies with this formulation
provided further evidence that co-delivery of gB and the polyepitope
as a single polypeptide was highly efficient in generating neutralizing
antibodies responses and virus-specific CD8
+ and CD4
+ Tc e l l
responses in a murine model and healthy virus carriers. Subse-
quently, we employed an experimental animal model system to
determine whether immunisation of HLA A2 transgenic mice with
Ad-gBCMVpoly is capable of reducing infection with a recombinant
vaccinia virus expressing HCMV antigens (i.e. gB and IE-1). These
mice not only showed induction of a strong CD4
+ and CD8
+ Tc e l l
response following immunisation but also acquired strong resistance
to virus infection.Interestingly,Ad-gBCMVpoly immunized showed
better protection against Vacc. gB when compared to Vacc.IE-1,
which suggested that gB-specific CD4
+ T cell responses could also
inhibit Vacc.gB virus.
Another important outcome of this study was the longevity of
the immune responses induced by the chimeric HCMV vaccine
which is particularly critical for the vaccine designed to control
congenital infection/disease where long-term memory response
over multiple years would be essential. Although the studies
outlined here does not allow any firm conclusions on the efficacy
of the chimeric polyepitope-based vaccine in humans, it does
clearly show that a formulation based on gB and HCMV T cell
epitopes can be used as immunogens to induce efficient humoral
and T cell responses in vivo. It is important to stress here that a
polyepitope-based vaccine for HCMV has a number of advantages
over the traditionally proposed vaccines, which are based on either
full-length HCMV antigens or synthetic peptide epitopes. There is
now convincing evidence that polyepitope proteins are extremely
unstable and are rapidly degraded by the proteasome dependent
pathway as a result of their limited secondary and tertiary
structure [18]. The rapid degradation of these polypeptides
dramatically enhances endogenous presentation of peptide
epitopes through the class I and II pathway. On the other hand
the full-length HCMV protein antigens are unlikely to be
degraded rapidly and may also initiate various intracellular
signalling events leading to the interference of presentation of
Figure 7. Expansion of gB-specific T cells following in vitro stimulation of human PBMC with Ad-gBCMVpoly. PBMC from a panel of
healthy virus carriers (referred to as D1–D17) were co-cultured with autologous PBMC infected with Ad-gBCMVpoly (MOI: 5:1 or 1:1) at a responder to
stimulator ratio of 2:1. These cultures were supplemented with rIL-2 (10 U/ml) on day 3 and every 3–4 days thereafter. On day 14, these T cell cultures
were tested against a panel of pooled overlapping gB peptides (20 aa long, overlapping by 10 aa) using intracellular cytokine assays. The data
presented in the figure shows the percentage of gB-specific CD8+ and CD4+ T cell recovered from each donor following stimulation with Ad-
gBCMVpoly.
doi:10.1371/journal.pone.0003256.g007
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based vaccine is likely to overcome any potential problem of
reinfection with different strains of HCMV and unique HLA types
in different ethnic groups of the world.
There is an emerging argument that HCMV vaccine efforts
should focus on the development of formulation(s) which are
designed to limit or prevent HCMV related diseases rather than to
prevent infection itself [11]. This contention is supported by
extensive studies in humans which revealed that although the
immune responses generated during natural HCMV infection are
unable to clear the latent virus, this response is sufficiently
competent to keep the virus under control and restrict virus
replication [13,14,15]. Furthermore, in immunocompromised
patients such as HIV-infected individuals and transplant recipi-
ents, HCMV related pathogenesis is generally due to reactivation
rather than primary infection. Considering the limited efficacy of
the currently available HCMV vaccine formulations in protecting
against infection in preclinical and clinical studies, we propose that
a vaccine to limit or prevent HCMV related disease rather than
infection itself is more realistic in the near future.
Materials and Methods
Construction of recombinant adenovirus encoding
HCMV polyepitope, gB and gB-HCMV polyepitope fusion
protein
The amino acid sequence of the 46 contiguous HLA class I and
class II-restricted T cell epitopes (Table 1) were translated to the
nucleotide sequence using human universal codon usage. Oligo-
nucleotides (102–107mer long) overlapping by 20 base pairs and
representing the polyepitope DNA sequence, were annealed
together by using Splicing by Overlap Extension and stepwise
asymmetric PCR [16]. The final PCR product was cloned into
pBluescript II KS
+ phagemid (Agilent Technologies, Melbourne,
Australia) encoded a Kozak sequence, Start methionine followed
by 46 contiguous HLA class I and class II-restricted epitopes. The
HCMV sequence encoding glycoprotein B (gB) was amplified
from the AD169 virus stock by PCR using gene specific primers.
This PCR product was designed to encode gB sequence from the
alanine residue at position 31 to valine at position 700 with the
deletion of the signal sequence. Following amplification the DNA
was cloned into pBluescript II KS
+ phagemid and confirmed by
DNA sequence analysis. For the expression of the gB-HCMV
polyepitope fusion protein the recombinant HCMV polyepitope
insert was excised from the pBluescript II KS
+ phagemid and
cloned into the gB pBluescript construct.
The assembly and production of the recombinant Ad5F35-based
adenoviruses was completed in three stages using a highly efficient,
ligation-based protocol of the Adeno-X System (CLONTECH, Palo
Alto,CA)(SeeFigure1).Firstly,insertswere excisedfromeachof the
constructs in pBluescript II KS
+ phagemid using Xba I/Kpn I
restriction enzymes and cloned into the pShuttle expression vector.
Following amplification in E.coli, the expression cassette from
pShuttle was excised using I-Ceu I/PI-Sec I homing enzymes and
cloned into an Ad5F35 expression vector. The recombinant Ad5F35
vector was transfected into human embryonic kidney (HEK) 293
cells, and the recombinant adenoviruses (referred to as Ad-
CMVpoly, Ad-gB and Ad-gBCMVpoly) were harvested from the
transfected cells by successive freeze-thawing cycles.
Synthesis of Peptides
Peptides, synthesized by the Merrifield solid phase method,
were purchased from Chiron Mimotopes (Melbourne, Australia),
dissolved in dimethyl sulphoxide, and diluted in serum-free RPMI
1640 medium for use in standard T cell assays. Purity of these
peptides were tested by mass spectrometery and showed .90%
purity
Figure 8. Ex vivo stimulation of human PBMC with Ad-
gBCMVpoly. PBMC from healthy virus carriers were co-cultured with
autologous PBMC infected with Ad-gBCMVpoly (MOI: 5:1) at a responder
to stimulator ratio of 2:1 for 6 h. These T cells were then co-stained with
anti-CD3, anti-CD8, PE-labelled anti-INF-c antibody and APC-labelled
MHC-peptide multimers. A–F,P e r c e n t a g eo fC D 8 + T cells expressingINF-c
following mock stimulation or Ad-gBCMVpoly stimulation. G–L,P e r c e n t -
age of MHC-peptide pentamer-positive cells expressing IFN-c following
mock stimulation or Ad-gBCMVpoly stimulation. Pentamers used for each
of the HCMV epitopes are indicated in G–L.
doi:10.1371/journal.pone.0003256.g008
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HLA A2 transgenic mice (referred to as HHD-2) [52], were
maintained under conventional conditions the animal facility at the
Queensland Institute of Medical Research. These mice are knocked
out for b2 microglobulin and H-2D
b and transgenic for a chimeric
HLA-A2.1 with the a3 domain derived from H-2D
b to allow
interaction with murine CD8 and a covalently attached human b2
microglobulin. These mice were immunised with varying doses of
plaque forming units (PFU) of recombinant viruses (Ad-CMVpoly,
Ad-CMVgB and Ad-gBCMVpoly) and HCMV-specific humoral
and cellular immune responses were evaluated at various time
points. Protocols were approved by QIMR animal ethics committee.
ELISpot assay
The ELISPOT assay was used to detect HLA A2-restricted
HCMV epitope-specific T cells following stimulation with synthetic
peptide(s) as described previously [13]. Briefly, 2610
5 responding
cells wereincubatedintriplicatewith each peptideepitope (1 mg/ml)
for 18 to 20 hrs in 96- well Multiscreen HA filtration plates (MAHA
S4150, Millipore, Bedford, MA) coated with anti-IFN-c monoclonal
antibody(Mabtech AB,Nacka, Sweden). Afterincubation,theplates
were extensively washed with Phosphate buffered saline with 0.5%
Tween20andincubatedwith asecondbiotinylatedanti-IFN-c mAb
followed by the addition of streptavidin conjugated alkaline
phosphatase. Cytokine producing cells were detected as purple spots
after a 30-min reaction with 5-bromo-4-chloro-3-indolyl phosphate
and nitro blue tetrazolium. Spots were counted automatically using
image analysis software. T cell precursor frequencies for each
peptide epitope were based on the total number of cells and the
number of spot forming cells (SFC) per well (average of 3 wells).
Epitope-specific spots were calculated after subtraction of the
number of spots in control wells consisting of cells without added
peptide (average of six wells).
Intracellular Cytokine Staining
Splenocytes from immunised mice or T cells from human donors
were incubated for overnight at 37uC with HCMV peptide epitopes
(1 mg/ml), or stimulator cells either pre-coated with HCMV peptide
epitopes (1 mg/ml) or infected with recombinant vaccinia virus
encoding HCMV antigens, in growth medium. Brefeldin A (BD
Pharmingen, San Diego, CA) was added during the last 5 hour-
incubation. For CD107a staining, anti-CD107a antibody was added
one hour before the adding of Brefeldin A. These cells were then
washed and incubated with PerCP-conjugated anti-CD8, FITC
conjugated anti-CD4 and Allophycocyanin-conjugated anti-CD3 at
4uC for 30 mins. Cells were washed, then fixed and permeabilised
with cytofix/cytoperm (BD Pharmingen) at 4uC for 20 minutes.
Cells were then washed in perm/wash (BD Pharmingen), incubated
with anti-IFN-c and anti-TNF-a mAbs (BD Pharmingen) at 4uCf o r
30 mins, washed again with perm/wash, resuspended in PBS and
analysed on a FACS Canto.
Expansion of HCMV specific T-cells from healthy donors
using Ad-gBCMVpoly
A panel of 17 human volunteers were recruited for this study.
Each volunteer was asked to sign the consent form as outlined in the
institutional ethics guidelines. For the expansion of specific T-cells,
peripheral blood mononuclear cells (PBMC) were co-cultured in
multi-well tissue culture plates in growth medium with either PBMC
(2,000 rad) infected with Ad-gBCMVpoly (MOI of 10:1) at a
responder to stimulator ratio of 2:1. On day 3, and every 3–4 days
thereafter, the cultures were supplemented with growth medium
containing recombinant IL-2 (kindly donated by NIH AIDS
Research & Reference Reagent Program). These T-cell cultures
were assessed for HCMV epitope-specific reactivity on days 10–17.
ELISA assay for anti-gB and anti-adenovirus antibody
Serum anti-gB or anti-adenovirus antibody titres were evaluated
by ELISA as previously described [53]. Briefly, PVL microplate 96-
well plates (MP Biomedicals, Sydney, Australia) pre-coated with
recombinant HCMV gB protein or adenovirus were incubated with
serially diluted serum samples for 2 hours at room temperature.
After washing with PBS-Tween-20 (PBST), plates were incubated
with HRP-conjugated sheep anti-mouse Ig antibody (murine
samples) or HRP-conjugated sheep anti-human Ig antibody (human
samples) for 1 hour. These plates were washed and incubated with
3.39,5 . 5 9-tetramethylbenzidine substrate solution (PanBio, Brisbane,
Australia) and the OD at 450 nm was analysed using an ELISA
reader. The isotypes of anti-gB antibodies in serum samples were
determined by ELISA as described above using the mouse
monoclonal antibody isotyping reagent kit (Sigma, IS02-1 kit,
Sydney, Australia) according to the manufacturer’s protocol.
Antibody avidity was evaluated as previously described [54].
Briefly after incubation of plates with serum samples as described
above, 5 M Urea (in PBST) was then added to half of the wells for
dissociation and the other half received PBST without urea. After
incubation for 30 min, plates were washed with PBST and
incubated with HRP-conjugated sheep anti-mouse Ig antibody
(murine samples) or HRP-conjugated sheep anti-human Ig
antibody (human samples) for 1 hour and completed using the
standard ELISA. The avidity indices were calculated as the ratio of
the OD values with urea divided by the OD values without urea
and expressed as a percentage.
CMV microneutralization assay
The neutralizing activity of the anti-gB antibody response in
vaccinated animals was assessed as described previously [23]. Briefly
serum samples were initially incubated at 56uC for 30 minutes to
inactivate complement, followed by serial dilution (25 ml/well) with
DMEM medium in 96-well ‘‘U’’ bottom plates. In each well an
equal volume of HCMV Ad169 was added and incubated at 37uC
for 2 h. This virus was then transferred to infect monolayer of
human fibroblast MRC-5 cell culture in 96 well flat bottom plates
with 80–90% confluence. After 2 h, plates were washed with
DMEMand 200 ml DMEM with 10%FCS wereadded to each well
and thenincubated at 37uC for 16–18 h.Afterincubation,cells were
fixedin100%methanol,incubatedwithperoxidaseblockingreagent
(Chemicon, S2001) and then reacted with mouse anti-CMV IE-1/
IE-2 monoclonal antibody (Clone MAB810, Chemicon) followed by
HRP-conjugated sheep anti-mouse Ig (Chemicon, AP326P). Finally
cells were stained with DAB+ substrate (Chemicon, K3467)
according to manufacturer’s protocol. The numbers of nuclei with
brown colour staining were counted using inverted microscope. The
neutralizing titre was calculated as the reciprocal of sera dilution that
gave 50% inhibition of IE-1/IE-2-expressing nuclei.
Vaccinia virus recombinant
Recombinant vaccinia constructs encoding HCMV antigens IE-
1 (Vacc.IE-1), gB (Vacc.gB) and a negative control vaccinia virus
construct made by insertion of the pSC11 vector alone, which is
negative for thymidine kinase (Vacc.TK
2), have been previously
described [13].
Protection assay
HHD-2 mice were intramuscularly immunised with the
indicated vaccine on day 0, followed by intraperitoneal challenge
Prophylactic Vaccine for HCMV
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HCMV antigens (Vacc.IE1 or Vacc.gB) at a dose of 10
7 pfu/
mouse on day 21. Mice were then sacrificed 4 days later, spleens
collected to evaluate epitope-specific T cell response by IFN-c ICS
assay, ovaries collected to determine vaccinia virus load by plaque
assay on monkey fibroblast CV-1 cells, and sera collected to
evaluate anti-gB Ab titres by ELISA. To determine vaccinia viral
titres, monolayers of CV-1 cells in a 6 well flat bottom plates were
incubated for 2 h at 37uC with serially diluted ovary lysates. After
incubation, 2 ml of RPMI1640 medium supplemented with 2%
FCS and 0.75% methylcellulose was added to each well and
incubated for further 3 days. After three days, plates were washed
with PBS and stained with crystal violet solution (Sigma, HT901)
at a working concentration (0.1% crystal violet in 15% ethanol) for
30 min and the number of plaques were counted using standard
procedures.
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